Table 3. Improvement in clinical symptoms since the last assessment, evaluated by the investigator after the first, fourth, and eighth treatment interval (3, 12, and 24 applications of the new IVIG, respectively) in SID patients.
| Improvement of clinical symptoms | After 3 IVIG applications (n = 27)* |
After 12 IVIG applications (n = 10)* |
After 24 IVIG applications (n = 10)* |
|---|---|---|---|
| Very good, N (%) | 4 (14.8%) | 3 (30.0%) | 1 (10.0%) |
| Good, N (%) | 20 (74.1%) | 7 (70.0%) | 8 (80.0%) |
| Moderate, N (%) | 3 (11.1%) | 0 (0.0%) | 1 (10.0%) |
| Not satisfactory, N (%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
*Excluding patients with missing data. IVIG = intravenous immunoglobulins; n = number of patients with documented assessment of clinical symptom improvement; N (%) = number and percentage of patients in each category.